Lifeworks Advisors LLC increased its stake in Regeneron Pharmaceuticals by 31.5%, now holding 6,743 shares worth $4.8 million ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Jones Financial Companies Lllp increased its stake in Regeneron Pharmaceuticals by 107.7% in Q4, now holding 812 shares.

Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET ...

Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...

Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Morgan Stanley also adjusted its price target to $1,150, keeping an Overweight rating, and noted Regeneron's initiation of a dividend, potentially broadening its investor base. Bernstein reduced ...

Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching near-normal levels at 24 weeks.